Actively Recruiting
RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
Led by Xueqin Yang · Updated on 2023-11-21
44
Participants Needed
1
Research Sites
267 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Investigators established the efficacy evaluation criteria for tumor markers (RecistTM) in the preliminary research. Among patients with advanced non-small cell lung cancer, patients with positive driving genes are more likely to exhibit abnormalities in tumor markers, which suggests that this criteria may be more suitable for evaluating the efficacy of targeted therapy in driving gene positive patients. Moreover, The judgment rules of the prelimary criteria still need further improvement. Therefore, in order to broaden the application scope of the RecistTM criteria, further improve the evaluation rules of RecistTM criteria, and multi-dimensionally confirm the reliability of RecistTM criteria on efficacy evaluation, investigators plan to conduct research on the application of RecistTM criteria in evaluating the efficacy of targeted therapy for advanced non-small cell lung cancer with positive driving genes.
CONDITIONS
Official Title
RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- NSCLC patients with stage IIIB-IV
- Positive driving genes (EGFR, ALK, C-MET, ROS, RET, HER2)
- Receiving first line targeted therapy
- Performance status 0-2 on ECOG criteria
- At least one tumor marker more than three times above normal: CEA >15 ng/ml, CA-199 >105 U/ml, CA-125 >105 U/ml, NSE >60 ng/ml, SCCAg >7.5 ng/ml, CYFRA21-1 >21 ng/ml
- Presence of measurable lesions
- Age 18 years or older
- Adequate blood, liver, and kidney function
- Informed consent given by patient or relative
You will not qualify if you...
- Patients with difficulty swallowing (dysphagia)
- Unable to take medication on time
- History of psychotropic substance abuse with inability to quit or mental disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Center, Dapping Hospital, Army Medical Center of PLA
Chongqing, Chongqing Municipality, China, 400042
Actively Recruiting
Research Team
X
Xueqin Yang, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here